ASTM F 3089 : 2014
Superseded
A superseded Standard is one, which is fully replaced by another Standard, which is a new edition of the same Standard.
View Superseded by
Standard Guide for Characterization and Standardization of Polymerizable Collagen-Based Products and Associated Collagen-Cell Interactions
Hardcopy , PDF
17-03-2023
English
10-07-2014
CONTAINED IN VOL. 13.02, 2014 Gives characteristics, properties, test methods, and standardization approaches for use by producers, manufacturers, and researchers to identify specific collagen polymer formulations and associated self-assembled collagenbased products produced with these formulations.
Committee |
F 04
|
DocumentType |
Guide
|
Pages |
17
|
PublisherName |
American Society for Testing and Materials
|
Status |
Superseded
|
SupersededBy |
1.1This guide for characterizing polymerizable collagens is intended to provide characteristics, properties, test methods, and standardization approaches for use by producers, manufacturers, and researchers to identify specific collagen polymer formulations and associated self-assembled collagen-based products produced with these formulations. This guide will focus on the characterization of polymer forms of Type I collagen, which is the most abundant collagen in mammalian connective tissues and organs, including skin, bone, tendon, and blood vessels. Type I collagen may be derived from a variety of sources including, but not limited to, animal or cadaveric tissues, cell culture, recombinant, and chemical synthesis. This guide is intended to focus on purified Type I collagen polymers as a starting material for wound and hemostatic dressings, surgical implants, substrates for tissue-engineered medical products (TEMPs), delivery vehicles for therapeutic cells or molecules, and 3D in-vitro tissue systems for basic research, drug development, and toxicity testing. Polymerizable or self-assembly implies that the collagen composition exhibits spontaneous macromolecular assembly from its components in the absence of the addition of exogenous factors including cross-linking agents. Self-assembling collagen polymers may include, but are not limited to: (1) tissue-derived atelocollagens, monomers, and oligomers; (2) collagen proteins and peptides produced using recombinant technology; and (3) chemically synthesized collagen mimetic peptides. It should be noted that the format of associated self-assembled collagen-based products also will vary and may include injectable solutions that polymerize in situ as well as preformed sheets, particles, spheres, fibers, sponges, matrices/gels, coatings, films, and other forms. This guide may serve as a template for characterization and standardization of other fibrillar collagen types that demonstrate polymerization or self-assembly.
1.2The ability of self-assembled collagen materials to guide cellular responses through provision of cellular adhesion and proteolytic domains as well as physical constraints (for example, structural, cell-matrix traction force) has been well documented through extensive clinical (1, 2)2 and basic research studies (3, 4). The biocompatibility and appropriateness of use for a specific application(s) is the responsibility of the product manufacturer.
1.3The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.
1.4Warning—Mercury has been designated by the Environmental Protection Agency (EPA) and many state agencies as a hazardous material that can cause central nervous system, kidney, and liver damage. Mercury, or its vapor, may be hazardous to health and corrosive to materials. Caution should be taken when handling mercury and mercury-containing products. See the applicable product Material Safety Data Sheet (MSDS) for details and the EPA website (http://www.epa.gov/mercury/faq.htm) for additional information. Users should be aware that selling mercury or mercury-containing products, or both, in your state may be prohibited by state law.
1.5The following precautionary caveat pertains only to the test method portion, Section 5, of this guide. This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.
ASTM F 3510 : 2021 | Standard Guide for Characterizing Fiber-Based Constructs for Tissue-Engineered Medical Products |
ASTM F 1251 : 1989 : R1995 | Standard Terminology Relating to Polymeric Biomaterials in Medical and Surgical Devices |
ASTM F 1904 : 1998 : R2003 | Standard Practice for Testing the Biological Responses to Particles In Vivo |
ASTM F 1983 : 1999 : R2008 | Standard Practice for Assessment of Compatibility of Absorbable/Resorbable Biomaterials for Implant Applications |
AAMI TIR19 : 1998 | GUIDANCE FOR ANSI/AAMI/ISO 10993-7: 1995, BIOLOGICAL EVALUATION OF MEDICAL DEVICES - PART 7: ETHYLENE OXIDE STERILIZATION RESIDUALS |
ISO 10993-3:2014 | Biological evaluation of medical devices — Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity |
ASTM F 1439 : 2003 | Standard Guide for Performance of Lifetime Bioassay for the Tumorigenic Potential of Implant Materials |
ASTM F 1983 : 1999 : R2003 | Standard Practice for Assessment of Compatibiltiy of Absorbable/Resorbable Biomaterials for Implant Applications |
ASTM F 756 : 2017 : REDLINE | Standard Practice for Assessment of Hemolytic Properties of Materials |
ASTM F 1906 : 1998 | Standard Practice for Evaluation of Immune Responses In Biocompatibility Testing Using ELISA Tests, Lymphocyte, Proliferation, and Cell Migration |
CFR 21(PTS200-299) : 0 | FOOD AND DRUGS - FOOD AND DRUG ADMINISTRATION, CHAPTER 1 DEPARTMENT OF HEALTH AND HUMAN SERVICES - PARTS 200-299 |
ASTM F 1983 : 2014 : REDLINE | Standard Practice for Assessment of Selected Tissue Effects of Absorbable Biomaterials for Implant Applications |
ASTM F 1904 : 1998 : EDT 1 | Standard Practice for Testing the Biological Responses to Particles In Vivo |
ASTM F 763 : 2022 | Standard Practice for Short-Term Intramuscular Screening of Implantable Medical Device Materials |
ASTM F 2148 : 2006 : REV A | Standard Practice for Evaluation of Delayed Contact Hypersensitivity Using the Murine Local Lymph Node Assay (LLNA) |
ASTM F 1903 : 2010 | Standard Practice for Testing For Biological Responses to Particles <i>In Vitro</i> |
ASTM F 763 : 2004 : R2016 | Standard Practice for Short-Term Screening of Implant Materials |
ASTM F 2148 : 2013 | Standard Practice for Evaluation of Delayed Contact Hypersensitivity Using the Murine Local Lymph Node Assay (LLNA) |
ASTM F 1439 : 2003 : R2008 | Standard Guide for Performance of Lifetime Bioassay for the Tumorigenic Potential of Implant Materials |
ASTM F 1904 : 2014 | Standard Practice for Testing the Biological Responses to Particles <emph type="bdit" >in vivo</emph> |
ASTM F 1905 : 1998 | Standard Practice for Selecting Tests for Determining the Propensity of Materials to Cause Immunotoxicity |
ASTM F 2148 : 2007 | Standard Practice for Evaluation of Delayed Contact Hypersensitivity Using the Murine Local Lymph Node Assay (LLNA) |
CFR 21(PTS800-1299) : 0 | FOOD AND DRUGS - FOOD AND DRUG ADMINISTRATION, CHAPTER 1 DEPARTMENT OF HEALTH AND HUMAN SERVICES - PARTS 800-1299 |
ASTM F 749 : 2013 : REDLINE | Standard Practice for Evaluating Material Extracts by Intracutaneous Injection in the Rabbit |
ASTM F 2148 : 2018 | Standard Practice for Evaluation of Delayed Contact Hypersensitivity Using the Murine Local Lymph Node Assay (LLNA) |
ASTM F 1903 : 2010-07 | PRACTICE FOR TESTING FOR BIOLOGICAL RESPONSES TO PARTICLES IN VITRO |
ISO 22442-1:2015 | Medical devices utilizing animal tissues and their derivatives Part 1: Application of risk management |
ASTM F 2148 : 2007 : R2012 | Standard Practice for Evaluation of Delayed Contact Hypersensitivity Using the Murine Local Lymph Node Assay (LLNA) |
ASTM F 2148 : 2007 : EDT 1 | Standard Practice for Evaluation of Delayed Contact Hypersensitivity Using the Murine Local Lymph Node Assay (LLNA) |
ASTM F 1439 : 2003 : R2018 | Standard Guide for Performance of Lifetime Bioassay for the Tumorigenic Potential of Implant Materials |
ASTM E 1298 : 1989 : R2000 | Standard Guide for Determination of Purity, Impurities, and Contaminants in Biological Drug Products |
ASTM E 1298 : 1989 : R1994 | Standard Guide for Determination of Purity, Impurities, and Contaminants in Biological Drug Products |
ISO 10993-10:2010 | Biological evaluation of medical devices Part 10: Tests for irritation and skin sensitization |
ISO 13408-1:2008 | Aseptic processing of health care products — Part 1: General requirements |
ASTM F 1904 : 1998 : R2008 | Standard Practice for Testing the Biological Responses to Particles <i>in vivo</i> |
ASTM F 2148 : 2001 | Standard Practice for Evaluation of Delayed Contact Hypersensitivity Using the Murine Local Lymph Node Assay (LLNA) |
ASTM E 1298 : 2006 | Standard Guide for Determination of Purity, Impurities, and Contaminants in Biological Drug Products (Withdrawn 2014) |
ASTM F 1903 : 1998 | Standard Practice for Testing for Biological Responses to Particles In Vitro |
ASTM F 619 : 2014 : REDLINE | Standard Practice for Extraction of Medical Plastics |
CFR 21(PTS300-499) : 0 | FOOD AND DRUGS - FOOD AND DRUG ADMINISTRATION, CHAPTER 1 DEPARTMENT OF HEALTH AND HUMAN SERVICES - PARTS 300-499 |
ISO 10993-17:2002 | Biological evaluation of medical devices — Part 17: Establishment of allowable limits for leachable substances |
ASTM F 763 : 1999 | Standard Practice for Short-Term Screening of Implant Materials |
ASTM F 748 : 2016 : REDLINE | Standard Practice for Selecting Generic Biological Test Methods for Materials and Devices |
ASTM F 1905 : 1998 : R2003 | Standard Practice for Selecting Tests for Determining the Propensity of Materials to Cause Immunotoxicity (Withdrawn 2011) |
ASTM F 1439 : 2002 | Standard Guide for Performance of Lifetime Bioassay for the Tumorigenic Potential of Implant Materials |
ASTM F 720 : 2017 : REDLINE | Standard Practice for Testing Guinea Pigs for Contact Allergens: Guinea Pig Maximization Test |
ISO 10993-1:2009 | Biological evaluation of medical devices Part 1: Evaluation and testing within a risk management process |
ASTM F 1903 : 2018 | Standard Practice for Testing for Cellular Responses to Particles <emph type="bdit" >in vitro</emph> |
ISO 22442-2:2015 | Medical devices utilizing animal tissues and their derivatives Part 2: Controls on sourcing, collection and handling |
ASTM F 1904 : 2014 : REDLINE | Standard Practice for Testing the Biological Responses to Particles <emph type="bdit" >in vivo</emph> |
ISO 10993-9:2009 | Biological evaluation of medical devices Part 9: Framework for identification and quantification of potential degradation products |
ASTM F 1983 : 2014 | Standard Practice for Assessment of Selected Tissue Effects of Absorbable Biomaterials for Implant Applications |
ISO 22442-3:2007 | Medical devices utilizing animal tissues and their derivatives — Part 3: Validation of the elimination and/or inactivation of viruses and transmissible spongiform encephalopathy (TSE) agents |
ISO 14971:2007 | Medical devices Application of risk management to medical devices |
ASTM F 1906 : 1998 : R2003 | Standard Practice for Evaluation of Immune Responses In Biocompatibility Testing Using ELISA Tests, Lymphocyte, Proliferation, and Cell Migration (Withdrawn 2011) |
ASTM F 1439 : 1992 : R1996 | Standard Guide for Performance of Lifetime Bioassay for the Tumorigenic Potential of Implant Materials |
ASTM F 1251 : 1989 : R2003 | Standard Terminology Relating to Polymeric Biomaterials in Medical and Surgical Devices (Withdrawn 2012) |
ASTM F 1439 : 2003 : R2013 | Standard Guide for Performance of Lifetime Bioassay for the Tumorigenic Potential of Implant Materials |
ASTM F 1983 : 1999 | Standard Practice for Assessment of Compatibiltiy of Absorbable/Resorbable Biomaterials for Implant Applications |
Access your standards online with a subscription
Features
-
Simple online access to standards, technical information and regulations.
-
Critical updates of standards and customisable alerts and notifications.
-
Multi-user online standards collection: secure, flexible and cost effective.